Intra-Articular Dexmedetomidine: A Treatment for Chronic Knee Pain
Chronic knee osteoarthritis (KOA) is a painful condition with limited treatment options. Non-pharmacological approaches often fall short, leading to decreased quality of life. Ozone therapy, a simple and affordable treatment, has shown promise for pain relief. Dexmedetomidine (DEX), a sedative and analgesic, has been u
| Condition(s) | Chronic Knee Pain |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Chronic knee osteoarthritis (KOA) is a painful condition with limited treatment options. Non-pharmacological approaches often fall short, leading to decreased quality of life. Ozone therapy, a simple and affordable treatment, has shown promise for pain relief. Dexmedetomidine (DEX), a sedative and analgesic, has been used successfully as an adjuvant to anesthesia and local anesthetics. Given its potential for pain management, exploring DEX as a treatment for KOA could offer a new and promising approach. |
| Who can participate | Inclusion Criteria: * Patients were not assigned for surgical intervention; * Patients were free of exclusion criteria Exclusion Criteria: * Patients were assigned for surgical intervention; * Patients who had uncontrolled hypertension and/or diabetes mellitus; * Patients who had uncompensated cardiac, renal, or hepatic diseases; * Patients with coagulopathy, spinal deformity, allergy, or contraindication for the used drugs; * Patients who refused to sign the informed consent were excluded from the study. |
| Ages | 40 Years to 75 Years |
| Sex | All |
| Lead sponsor | Tanta University |
| Locations | Tanta, El Gharbyia, Egypt |
| Start date | 2024-09-17 |
| NCT ID | NCT06641206 |
| Official listing | https://clinicaltrials.gov/study/NCT06641206 |